Biophytis Temporarily Suspends Share Trading

Biophytis SA, a biotechnology company focused on treatments for age-related diseases, has temporarily halted the trading of its shares on Euronext Growth Paris. This suspension, effective since June 17, 2025, is due to the delay in publishing the company's annual financial report for the fiscal year ending December 31, 2024. The report is pending certification by statutory auditors, anticipated by the end of June 2025.

The company plans to resume trading once the financial report is published, and Biophytis has committed to keeping the market informed of further developments. The decision underscores the compliance with financial regulations, reflecting the importance of transparency and accountability in maintaining shareholder trust.